{"id":452042,"date":"2021-03-05T16:33:10","date_gmt":"2021-03-05T21:33:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452042"},"modified":"2021-03-05T16:33:10","modified_gmt":"2021-03-05T21:33:10","slug":"dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/","title":{"rendered":"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Montrouge, France, March 5, 2021<\/p>\n<p align=\"left\">\n        <strong>DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference<\/strong>\n      <\/p>\n<p align=\"justify\">DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass\u00e9, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021.<\/p>\n<p align=\"justify\">A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors &amp; Media section of the Company\u2019s website beginning Tuesday, March 9<sup>th<\/sup> at 7:00 a.m. ET: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jYDnVyZG4vYGv0gb7KeNM8vGwCXcyxLEkDNEwfJK_eq1DYFCugnxqrM0ro1c8aMTNU6HT8yRAdP2U1xWjH5upbuPytc3EWzVej5sNOg3oLMQCG-ijLrv4u-qZCBTlh_hqLjRkD7vbgpCeH8WyWb3zcQq5j7mBonY60mh3wi0Sss=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/www.dbv-technologies.com\/investor-relations\/<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About DBV Technologies<\/strong><br \/>\n        <br \/>DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, DBV\u2019s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV\u2019s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company\u2019s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact <\/strong><br \/>\n        <br \/>Anne Pollak<br \/>DBV Technologies<br \/>+1 857-529-2363<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mQ9rHwBaZkyl6i9dB8_1DrOlTJQB3DM3OR0cJ97bmsj-yLxW0-PirMo9BGLC7cm6ajiRlEbCVHOwrjOzu0MAvrV0JOeLbeFJ8n58Q8vlQ61FMl-OYCQdysYU3vtjK0UI\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>anne.pollak@dbv-technologies.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Angela Marcucci<br \/>DBV Technologies<br \/>+1\u00a0646-842-2393<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nxE4wHzvBh4BUwPYEyjLSxookkngdNoQ-YisU1wiOWVrUez7iZ5mmDG36ZCHN-ed-ZAzIZ9G25ZbgzsoR4met1bEbMt9Hkr4qc2ZaP4R7UnK2CyTJDrh07Z5L-YGZIS6Rj8aKCOn6IxcfhoQP1M4vA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/23f91977-6758-491b-a04d-226ea94a94fa\" rel=\"noopener noreferrer\">PDF Version<\/a>\n        <\/li>\n<\/ul>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/5319f9e0-746b-4fa5-95dd-917c09f44699\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass\u00e9, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021. A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors &amp; Media section of the Company\u2019s website beginning Tuesday, March 9th at 7:00 a.m. ET: https:\/\/www.dbv-technologies.com\/investor-relations\/. About DBV Technologies DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, DBV\u2019s method of delivering &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452042","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass\u00e9, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021. A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors &amp; Media section of the Company\u2019s website beginning Tuesday, March 9th at 7:00 a.m. ET: https:\/\/www.dbv-technologies.com\/investor-relations\/. About DBV Technologies DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, DBV\u2019s method of delivering &hellip; Continue reading &quot;DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T21:33:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference\",\"datePublished\":\"2021-03-05T21:33:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/\",\"name\":\"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==\",\"datePublished\":\"2021-03-05T21:33:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","og_description":"Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass\u00e9, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021. A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors &amp; Media section of the Company\u2019s website beginning Tuesday, March 9th at 7:00 a.m. ET: https:\/\/www.dbv-technologies.com\/investor-relations\/. About DBV Technologies DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, DBV\u2019s method of delivering &hellip; Continue reading \"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T21:33:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference","datePublished":"2021-03-05T21:33:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/","name":"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==","datePublished":"2021-03-05T21:33:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MDY1NyM0MDA4Nzk4NjQjMTAxMTE1Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452042"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452042\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}